Akeso’s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA by Investing.com
Hong Kong, January 26, 2025 /prnewswire/- Akeso, Inc. (9926.hk)("AkesoThe Company (or the…
evitria partners with Sapio Sciences to streamline antibody workflow management and reporting
Sapio ScienceEvitria, a leader in antibody expression services, is a Science-aware™ laboratory…
